| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Common Stock | Options Exercise | $415,156 | +4,715 | +20% | $88.05 | 27,896 | 30 Oct 2021 | Direct | |
| transaction | MRK | Common Stock | Tax liability | $204,540 | -2,323 | -8.3% | $88.05 | 25,573 | 30 Oct 2021 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Restricted Stock Unit | Options Exercise | $0 | -4,715 | -100% | $0.000000* | 0 | 30 Oct 2021 | Common Stock | 4,715 | Direct | F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | Holdings include shares acquired in dividend reinvestment transactions. |
| F2 | Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. |
| F3 | Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. |
| F4 | The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. |